InMode Ltd. Ordinary Shares (INMD)
InMode Ltd. is a medical technology company specializing in minimally invasive aesthetic and medical treatment solutions. The company's devices utilize radio-frequency technology to deliver non-invasive procedures for body contouring, skin tightening, and other dermatological applications. Founded in 2001 and headquartered in Israel, InMode's products are used by medical and cosmetic practitioners worldwide to offer safer, more efficient treatments.
Company News
InMode Ltd. announced participation in two investor conferences in August 2025, including the Needham Virtual MedTech & Diagnostics Conference and Canaccord 45th Annual Global Growth Conference, featuring presentations by their CEO and CFO.
The global cosmetic surgery market is expected to grow from $67.2 billion in 2023 to $207.6 billion by 2033, at a CAGR of 11.7%. The market is driven by the growing acceptability and desire for less invasive treatments, with surgical procedures and the female segment holding the highest market share.
InMode reported Q3 2024 earnings, with revenue and guidance missing expectations due to macroeconomic headwinds and a slowdown in minimally invasive treatments. The company is optimistic about its new platforms, IgniteRF and OptimasMAX, and is making organizational changes to align its target market.
InMode's business seems heavily reliant on economic conditions, beyond management's control. See why INMD stock is a Hold.
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -133.33% and 15.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?